Patents by Inventor Gudmundur Johannsson
Gudmundur Johannsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10583146Abstract: The invention relates to glucocorticoid replacement therapy and provides pharmaceutical compositions and kits designed to deliver one or more glucocorticoids to a subject in need thereon in a manner that results in serum levels of the glucocorticoid that essentially mimic that of a healthy subject for a clinically relevant period of time. The pharmaceutical compositions and kits are prepared in such a way that a first part of one or more glucocorticoids is substantially immediately released and a second part of one or more glucocorticoids is released over an extended period of time of at least about 8 hours. The invention also relates to a method for treating diseases requiring glucocorticoid treatment such as in subjects having a glucocorticoid deficiency disorder.Type: GrantFiled: April 17, 2014Date of Patent: March 10, 2020Assignee: SHIRE VIROPHARMA INCORPORATEDInventors: Stanko Skrtic, Jörgen Johnsson, Hans Lennernäs, Thomas Hedner, Gudmundur Johannsson
-
Patent number: 10413555Abstract: The aim of the present study was to investigate the effect of a combination of triiodothyroacetic acid (TRIAC) and dehydroepiandrosterone (DHEA) compared with TRIAC, DHEA or placebo alone on corticosteroid induced effect on collagen synthesis in humans. Six healthy male human volunteers aged 40-65 participated. Four areas of abdominal skin were pre-treated for 3 weeks with betamethasone valerate cream. The same areas were then treated with one of the following alternatives in the same cream vehicle: TRIAC, DHEA, TRIAC+DHEA and placebo for 2 weeks. Then suction blisters were raised in each of these areas with a vacuum pump. The blister fluid from each area was collected and frozen until analysis. Analysis of amino terminal propeptide of human type I procollagen (PINP) in suction blister fluid was performed using a commercially available immunoassay (Orion Diagnostics) kit.Type: GrantFiled: November 24, 2015Date of Patent: September 17, 2019Assignee: TROPHEA DEVELOPMENT ABInventors: Jan Faergemann, Gudmundur Johannsson, Claes Ohlsson, Derek Gregory Batcheller, Jörgen Johnsson, Jan Törnell
-
Publication number: 20190216822Abstract: The aim of the present study was to investigate the effect of a combination of triiodothyroacetic acid (TRIAC) and dehydroepiandrosterone (OHEA) compared with TRIAC, DHEA or placebo alone on corticosteroid induced effect on collagen synthesis in humans. Six healthy male human volunteers aged 40-65 participated. Four areas of abdominal skill were pre-treated for 3 weeks with betamethasone valerate cream. The same areas were then treated with one of the following alternatives in the same cream vehicle: TRIAC, DHKA, TWAC+DHEA and placebo for 2 weeks. Then suction blisters were raised in each of these areas with a vacuum pump. The blister fluid from each area was collected and frozen until analysis. Analysis of amino terminal propeptide of human type I procollagen (MNP) in suction blister fluid was performed using a commercially available immunoassay (Orion Diagnostics) kit.Type: ApplicationFiled: March 22, 2019Publication date: July 18, 2019Applicant: TROPHEA DEVELOPMENT ABInventors: Jan Faergemann, Gudmundur Johannsson, Claes Ohlsson, Derek Gregory Batcheller, Jörgen Johnsson, Jan Törnell
-
Patent number: 10285997Abstract: The aim of the present study was to investigate the effect of a combination of triiodothyroacetic acid (TRIAC) and dehydroepiandrosterone (DHEA) compared with TRIAC, DHEA or placebo alone on corticosteroid induced effect on collagen synthesis in humans. Six healthy male human volunteers aged 40-65 participated. Four areas of abdominal skin were pre-treated for 3 weeks with betamethasone valerate cream. The same areas were then treated with one of the following alternatives in the same cream vehicle: TRIAC, DHEA, TRIAC+DHEA and placebo for 2 weeks. Then suction blisters were raised in each of these areas with a vacuum pump. The blister fluid from each area was collected and frozen until analysis. Analysis of amino terminal propeptide of human type I procollagen (PINP) in suction blister fluid was performed using a commercially available immunoassay (Orion Diagnostics) kit.Type: GrantFiled: November 24, 2015Date of Patent: May 14, 2019Assignee: TROPHEA DEVELOPMENT ABInventors: Jan Faergemann, Gudmundur Johannsson, Claes Ohlsson, Derek Gregory Batcheller, Jörgen Johnsson, Jan Törnell
-
Patent number: 9925139Abstract: The present invention relates to glucocorticoid-containing pharmaceutical compositions or kits for use in acute emergency situations where acute glucocorticoid therapy is required. Notably, the invention relates to pharmaceutical compositions and kits that are designed to be administered by non-medically trained persons outside a hospital or another medical or clinical setting. The invention also relates to a method for treating a disorder requiring acute glucocorticoid therapy by providing a fast onset of action of a glucocorticoid.Type: GrantFiled: April 21, 2005Date of Patent: March 27, 2018Assignee: ACUCORT ABInventors: Stanko Skrtic, Jörgen Johnsson, Hans Lennernäs, Thomas Hedner, Gudmundur Johannsson
-
Publication number: 20170319598Abstract: The aim of the present study was to investigate the effect of a combination of triiodothyroacetic acid (TRIAC) and dehydroepiandrosterone (DHEA) compared with TRIAC, DHEA or placebo alone on corticosteroid induced effect on collagen synthesis in humans. Six healthy male human volunteers aged 40-65 participated. Four areas of abdominal skin were pre-treated for 3 weeks with betamethasone valerate cream. The same areas were then treated with one of the following alternatives in the same cream vehicle: TRIAC, DHEA, TRIAC+DHEA and placebo for 2 weeks. Then suction blisters were raised in each of these areas with a vacuum pump. The blister fluid from each area was collected and frozen until analysis. Analysis of amino terminal propeptide of human type I procollagen (PINP) in suction blister fluid was performed using a commercially available immunoassay (Orion Diagnostics) kit.Type: ApplicationFiled: November 24, 2015Publication date: November 9, 2017Applicant: TROPHEA DEVELOPMENT ABInventors: Jan Faergemann, Gudmundur Johannsson, Claes Ohlsson, Derek Gregory Batcheller, Jörgen Johnsson, Jan Törnell
-
Publication number: 20150209375Abstract: The present invention relates to an improved method of administration of glucocorticoid based composition in glucocorticoid replacement therapies enabling an objectively based regimen for administration enabling correct individual dosing of glucocorticoids resulting in an optimized individual replacement therapy and thus an improved long-term outcome for patients with temporary or chronic adrenal insufficiency.Type: ApplicationFiled: April 2, 2015Publication date: July 30, 2015Inventors: Thomas Hedner, Ulrika Sigrida Helena Simonsson, Gudmundur Johannsson, Hans Lennernas, Stanko Skrtic
-
Publication number: 20140242167Abstract: The invention relates to glucocorticoid replacement therapy and provides pharmaceutical compositions and kits designed to deliver one or more glucocorticoids to a subject in need thereon in a manner that results in serum levels of the glucocorticoid that essentially mimic that of a healthy subject for a clinically relevant period of time. The pharmaceutical compositions and kits are prepared in such a way that a first part of one or more glucocorticoids is substantially immediately released and a second part of one or more glucocorticoids is released over an extended period of time of at least about 8 hours. The invention also relates to a method for treating diseases requiring glucocorticoid treatment such as in subjects having a glucocorticoid deficiency disorder.Type: ApplicationFiled: April 17, 2014Publication date: August 28, 2014Applicant: DuoCort Pharma ABInventors: Stanko SKRTIC, Jörgen JOHNSSON, Hans LENNERNÄS, Thomas HEDNER, Gudmundur JOHANNSSON
-
Publication number: 20130209565Abstract: The present invention relates to an improved method of administration of glucocorticoid based compositions in glucocorticoid replacement therapies enabling an objectively based regimen for administration enabling correct individual dosing of glucocorticoids resulting in an optimised individual replacement therapy and thus an improved long-term outcome for patients with temporary or chronic adrenal insufficiency.Type: ApplicationFiled: May 18, 2011Publication date: August 15, 2013Applicant: DuoCort Pharma ABInventors: Thomas Hedner, Ulrika Sigrid Helena Simonsson, Gudmundur Johannsson, Hans Lennernäs, Stanko Skrtic
-
Patent number: 8425937Abstract: The invention relates to glucocorticoid replacement therapy and provides pharmaceutical compositions and kits designed to deliver one or more glucocorticoids to a subject in need thereof in a manner that results in serum levels of the glucocorticoid that essentially mimic that of a healthy subject for a clinically relevant period of time. The pharmaceutical composition comprises one or more glucocorticoids, wherein a first part of one or more glucocorticoids is substantially immediately released and a second part of one or more glucocorticoids is released over an extended period of time of at least about 8 hours, and the amount of the one or more glucocorticoids of the first part, expressed as hydrocortisone equivalents, is in a range of from about 15 to about 50% of the total hydrocortisone equivalents.Type: GrantFiled: April 21, 2005Date of Patent: April 23, 2013Assignee: DuoCort Pharma ABInventors: Stanko Skrtic, Jörgen Johnsson, Hans Lennernäs, Thomas Hedner, Gudmundur Johannsson
-
Publication number: 20120183610Abstract: The present invention relates to improved glucocorticoid therapy and to treatment or prevention of a number of disorders that are due to a diminished or disrupted endogenous glucocorticoid secretory pattern. The invention is based on the findings that producing a specific serum Cortisol time profile that mimics the circadian rhythm of Cortisol of a healthy subject in a subject suffering from a diminished or disrupted glucocorticoid secretory pattern gives benefits with respect to reduction of side-effects.Type: ApplicationFiled: April 7, 2010Publication date: July 19, 2012Inventors: Hans Lennernäs, Jörgen Johnsson, Thomas Hedner, Gudmundur Johannsson, Stanko Skrtic
-
Publication number: 20090035375Abstract: The present invention relates to glucocorticoid-containing pharmaceutical compositions or kits for use in acute emergency situations where acute glucocorticoid therapy is required. Notably, the invention relates to pharmaceutical compositions and kits that are designed to be administered by non-medically trained persons outside a hospital or another medical or clinical setting.Type: ApplicationFiled: April 21, 2005Publication date: February 5, 2009Inventors: Stanko Skrtic, Jorgen Johnsson, Hans Lennernas, Thomas Hedner, Gudmundur Johannsson
-
Publication number: 20080187586Abstract: The invention relates to glucocorticoid replacement therapy and provides pharmaceutical compositions and kits designed to deliver one or more glucocorticoids to a subject in need thereof in a manner that results in serum levels of the glucocorticoid that essentially mimic that of a healthy subject for a clinically relevant period of time. The pharmaceutical composition comprises one or more glucocorticoids, wherein a first part of one or more glucocorticoids is substantially immediately released and a second part of one or more glucocorticoids is released over an extended period of time of at least about 8 hours, and the amount of the one or more glucocorticoids of the first part, expressed as hydrocortisone equivalents, is in a range of from about 15 to about 50% of the total hydrocortisone equivalents.Type: ApplicationFiled: April 21, 2005Publication date: August 7, 2008Applicant: DUOCORT ABInventors: Stanko Skrtic, Jorgen Johnsson, Hans Lennernas, Thomas Hedner, Gudmundur Johannsson
-
Patent number: 7122515Abstract: A method for treating a patient having Metabolic Syndrome comprising Primary Insulin Resistance and exhibiting lipoprotein aberrations or hypertension comprises administering to said patient human growth hormone or a functional analog thereof in an amount effective for decreasing lipoprotein aberrations or hypertension of said patient.Type: GrantFiled: March 25, 2004Date of Patent: October 17, 2006Assignee: Pharmacia ABInventors: Gudmundur Johannsson, Per M{dot over (a)}rin, Lars Lönn, Malin Ottosson, Kaj Stenlöf, Per Björntorp, Lars Sjöström, Bengt-{dot over (A)}ke Bengtsson
-
Patent number: 6846800Abstract: Methods for treating a patient for insulin resistance to decrease the insulin resistance in a patient having Metabolic Syndrome comprising Primary Insulin Resistance and abdominal/visceral obesity comprise administering to the patient growth hormone or a functional derivative thereof in an amount effective for decreasing insulin resistance of the patient.Type: GrantFiled: March 31, 1998Date of Patent: January 25, 2005Assignee: Pharmacia ABInventors: Gudmundur Johannsson, Per Mårin, Lars Lönn, Malin Ottosson, Kaj Stenlöf, Per Björntorp, Lars Sjöström, Bengt-Åke Bengtsson
-
Publication number: 20050009744Abstract: The use of at least one first substance related to the growth hormone (GH) axis, and of at least one second substance, wherein the second substance upon administration to a patient leads to increased beta adrenergic receptor blockade, for the production of a pharmaceutical composition for the treatment of congestive heart failure (CHF) is disclosed. The use of the at least one first or second substance, respectively, for the production of a pharmaceutical composition for the treatment of congestive heart failure (CHF), intended for administration in combination with a pharmaceutical composition comprising the at least one second or first substance, respectively, is also disclosed. Also a method for treatment of congestive heart failure (CHF), wherein a pharmaceutically active amount of the at least one first substance is administered to a patient in combination with the administration to a patient of a pharmaceutically active amount of the at least one second substance is disclosed.Type: ApplicationFiled: November 8, 2002Publication date: January 13, 2005Inventors: Olle Isaksson, Jorgen Isgaard, Gudmundur Johannsson
-
Publication number: 20040180833Abstract: A method for treating a patient having Metabolic Syndrome comprising Primary Insulin Resistance and exhibiting lipoprotein aberrations or hypertension comprises administering to said patient human growth hormone or a functional analog thereof in an amount effective for decreasing lipoprotein aberrations or hypertension of said patient.Type: ApplicationFiled: March 25, 2004Publication date: September 16, 2004Inventors: Gudmundur Johannsson, Per Marin, Lars Lonn, Malin Ottosson, Kaj Stenlof, Per Bjorntorp, Lars Sjostrom, Bengt-Ake Bengtsson